CN110856446A - 抗pd-l1抗体及其用途 - Google Patents

抗pd-l1抗体及其用途 Download PDF

Info

Publication number
CN110856446A
CN110856446A CN201880025898.4A CN201880025898A CN110856446A CN 110856446 A CN110856446 A CN 110856446A CN 201880025898 A CN201880025898 A CN 201880025898A CN 110856446 A CN110856446 A CN 110856446A
Authority
CN
China
Prior art keywords
seq
antibody
nos
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880025898.4A
Other languages
English (en)
Chinese (zh)
Inventor
Y·拉夫罗夫斯基
许婷
S·巴巴索夫
A·雷皮克
M·萨姆索诺夫
V·伊格纳提夫
S·阿库阿泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Afam Overseas Co Ltd
Original Assignee
Afam Overseas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afam Overseas Co Ltd filed Critical Afam Overseas Co Ltd
Publication of CN110856446A publication Critical patent/CN110856446A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201880025898.4A 2017-04-18 2018-04-18 抗pd-l1抗体及其用途 Pending CN110856446A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2017028206 2017-04-18
USPCT/US2017/028206 2017-04-18
PCT/US2018/028206 WO2018195226A1 (en) 2017-04-18 2018-04-18 Anti-pd-l1 antibody and use thereof

Publications (1)

Publication Number Publication Date
CN110856446A true CN110856446A (zh) 2020-02-28

Family

ID=63856823

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880025898.4A Pending CN110856446A (zh) 2017-04-18 2018-04-18 抗pd-l1抗体及其用途

Country Status (17)

Country Link
US (1) US20210115143A1 (enExample)
EP (1) EP3612565A4 (enExample)
JP (2) JP2020517239A (enExample)
KR (1) KR102323960B1 (enExample)
CN (1) CN110856446A (enExample)
AU (1) AU2018256392B2 (enExample)
BR (1) BR112019021828B1 (enExample)
CA (1) CA3059447A1 (enExample)
CL (1) CL2019002953A1 (enExample)
CO (1) CO2019012118A2 (enExample)
EA (1) EA201900443A1 (enExample)
MA (1) MA50038A (enExample)
MX (1) MX2019012461A (enExample)
MY (1) MY199319A (enExample)
PH (1) PH12019502302A1 (enExample)
SG (1) SG11201909041SA (enExample)
WO (1) WO2018195226A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11046769B2 (en) * 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
JP7619941B2 (ja) 2018-11-14 2025-01-22 アイバイオ， インク． Ｃｄ２５抗体
CN113646330A (zh) * 2018-11-14 2021-11-12 鲁比克治疗股份有限公司 工程化cd25多肽及其用途
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
US12331120B2 (en) 2019-04-11 2025-06-17 Scripps Korea Antibody Institute Antibodies against programmed death-ligand 1 and uses thereof
AU2020261961B2 (en) * 2019-04-26 2022-07-07 I-Mab Biopharma Co., Ltd. Human PD-L1 antibodies
US20210403568A1 (en) * 2020-06-29 2021-12-30 Cai Gu Huang Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
WO2022031695A1 (en) * 2020-08-04 2022-02-10 Exelixis, Inc. Pd-l1 binding agents and uses thereof
TW202317640A (zh) * 2021-09-24 2023-05-01 大陸商廣東菲鵬製藥股份有限公司 一種抗人pd-l1人源化抗體或其抗原結合片段及其應用
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103602A1 (en) * 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US20150259414A1 (en) * 2014-02-20 2015-09-17 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
CN105777906A (zh) * 2014-12-19 2016-07-20 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
WO2016149201A2 (en) * 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US20160272712A1 (en) * 2013-10-25 2016-09-22 Dana-Farber Cancer Institute Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
CN109963589A (zh) * 2016-10-30 2019-07-02 上海复宏汉霖生物技术股份有限公司 抗-pd-l1抗体及变异体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
TWI729512B (zh) * 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160272712A1 (en) * 2013-10-25 2016-09-22 Dana-Farber Cancer Institute Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
WO2015103602A1 (en) * 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US20150259414A1 (en) * 2014-02-20 2015-09-17 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
CN105777906A (zh) * 2014-12-19 2016-07-20 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
WO2016149201A2 (en) * 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
CN109963589A (zh) * 2016-10-30 2019-07-02 上海复宏汉霖生物技术股份有限公司 抗-pd-l1抗体及变异体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GERHARD HAMILTON等: "Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity", 《EXPERT OPIN BIOL THER》, pages 515 - 523 *
MELISSA BERSANELLI AND SEBASTIANO BUTI: "From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis", 《WORLD J CLIN ONCOL.》, pages 37 *

Also Published As

Publication number Publication date
MA50038A (fr) 2020-07-08
SG11201909041SA (en) 2019-11-28
EP3612565A4 (en) 2021-06-16
WO2018195226A1 (en) 2018-10-25
KR20190141169A (ko) 2019-12-23
MY199319A (en) 2023-10-24
PH12019502302A1 (en) 2020-09-21
EA201900443A1 (ru) 2020-03-06
AU2018256392A1 (en) 2019-10-17
AU2018256392B2 (en) 2024-05-16
CA3059447A1 (en) 2018-10-25
CL2019002953A1 (es) 2020-01-10
MX2019012461A (es) 2019-12-11
JP2023025003A (ja) 2023-02-21
EP3612565A1 (en) 2020-02-26
JP2020517239A (ja) 2020-06-18
CO2019012118A2 (es) 2020-04-01
BR112019021828A2 (pt) 2020-03-24
BR112019021828B1 (pt) 2022-09-20
KR102323960B1 (ko) 2021-11-10
US20210115143A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
KR102323960B1 (ko) 항-pd-l1 항체 및 이의 용도
JP2021527441A (ja) Ｃｌｄｎ１８．２を標的とする抗体、二重特異性抗体、ａｄｃ及びｃａｒならびにその使用
WO2021058000A1 (zh) 抗人Claudin18.2抗体及其应用
CN105777906A (zh) 抗pd-l1全人抗体及其应用
JP2017532290A (ja) Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体
CN109641037A (zh) 抗psma抗体及其用途
CN114524878B (zh) 一种双特异性抗体及其用途
JP7457822B2 (ja) 抗ｃｄ３および抗ｃｄ１２３二重特異性抗体およびその使用
CN110229232A (zh) 双特异性抗体及其用途
CN112062855B (zh) 一种含有衔接器的药物治疗剂的开发和应用
WO2022171080A1 (zh) 抗cd112r抗体及其用途
US20250340631A1 (en) Cldn18.2-targeting antibody, bispecific antibody and use thereof
WO2023088337A1 (zh) 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
CN116396388B (zh) 一种抗b7-h3抗体及其应用
WO2023001155A1 (zh) 一种磷脂酰肌醇蛋白聚糖3抗体及其应用
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
TWI835166B (zh) 靶向pd-1和/或ox40的特異性結合蛋白及其應用
US12509520B2 (en) Anti-CD3 and anti-CD123 bispecific antibody and use thereof
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
TW202438528A (zh) 特異性結合Ｃｌａｕｄｉｎ １８．２的抗體及其製法和應用
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
EA044327B1 (ru) Антитело к pd-l1 и его применение
WO2024094159A1 (zh) 靶向人源ror1的单域抗体
CN117836321A (zh) 抗牛痘病毒抗原抗体以及相关组合物和方法
HK40066348B (zh) 靶向bcma的抗体、双特异性抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200228

RJ01 Rejection of invention patent application after publication